Have a feature idea you'd love to see implemented?
Let us know!
LEGN Legend Biotech Corp
Price (delayed)
$39.75
Market cap
$7.29B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.92
Enterprise value
$6.43B
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated
Highlights
The revenue has surged by 123% year-on-year and by 14% since the previous quarter
The gross margin has grown by 49% YoY and by 4.3% from the previous quarter
The EPS has increased by 35% year-on-year but it has declined by 25% since the previous quarter
The company's net income rose by 32% YoY but it fell by 22% QoQ
The quick ratio has contracted by 45% YoY
The equity is down by 17% YoY and by 3.7% from the previous quarter
Key stats
What are the main financial stats of LEGN
Market
Valuations
Earnings
Shares outstanding
183.45M
Market cap
$7.29B
Enterprise value
$6.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.49
Price to sales (P/S)
13.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.35
Revenue
$520.18M
EBIT
-$323.17M
EBITDA
-$301.26M
Free cash flow
-$214.28M
Per share
Balance sheet
Liquidity
EPS
-$1.92
Free cash flow per share
-$1.18
Book value per share
$6.12
Revenue per share
$2.85
TBVPS
$9.51
Total assets
$1.74B
Total liabilities
$619.72M
Debt
$346.59M
Equity
$1.12B
Working capital
$1.08B
Debt to equity
0.31
Current ratio
4.98
Quick ratio
4.48
Net debt/EBITDA
2.87
Margins
Efficiency
Dividend
EBITDA margin
-57.9%
Gross margin
62.9%
Net margin
-66.9%
Operating margin
-56.5%
Return on assets
-19.5%
Return on equity
-29.7%
Return on invested capital
-50.9%
Return on capital employed
-22.1%
Return on sales
-62.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEGN stock price
How has the Legend Biotech stock price performed over time
Intraday
-0.97%
1 week
-0.35%
1 month
-8.52%
1 year
-30.57%
YTD
-33.94%
QTD
-18.43%
Financial performance
How have Legend Biotech's revenue and profit performed over time
Revenue
$520.18M
Gross profit
$327.07M
Operating income
-$293.78M
Net income
-$348.13M
Gross margin
62.9%
Net margin
-66.9%
The revenue has surged by 123% year-on-year and by 14% since the previous quarter
Legend Biotech's net margin has surged by 69% YoY but it has decreased by 7% QoQ
The operating margin has soared by 66% YoY but it has decreased by 6% QoQ
The gross margin has grown by 49% YoY and by 4.3% from the previous quarter
Growth
What is Legend Biotech's growth rate over time
Valuation
What is Legend Biotech stock price valuation
P/E
N/A
P/B
6.49
P/S
13.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.35
The EPS has increased by 35% year-on-year but it has declined by 25% since the previous quarter
The stock's price to book (P/B) is 48% less than its 5-year quarterly average of 12.5 and 20% less than its last 4 quarters average of 8.1
The equity is down by 17% YoY and by 3.7% from the previous quarter
The revenue has surged by 123% year-on-year and by 14% since the previous quarter
The P/S is 77% less than the 5-year quarterly average of 60.4 and 45% less than the last 4 quarters average of 25.4
Efficiency
How efficient is Legend Biotech business performance
The return on sales has surged by 70% year-on-year but it has declined by 7% since the previous quarter
LEGN's return on assets is up by 40% year-on-year but it is down by 24% since the previous quarter
The company's return on equity rose by 40% YoY but it fell by 28% QoQ
LEGN's return on invested capital is up by 33% year-on-year but it is down by 29% since the previous quarter
Dividends
What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEGN.
Financial health
How did Legend Biotech financials performed over time
Legend Biotech's total assets is 180% more than its total liabilities
The quick ratio has contracted by 45% YoY
Legend Biotech's current ratio has decreased by 42% YoY but it has increased by 2.9% QoQ
Legend Biotech's debt is 69% lower than its equity
The debt to equity has grown by 29% YoY and by 7% from the previous quarter
The equity is down by 17% YoY and by 3.7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.